Signal #136282 · SEC 8-K

$LYEL SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $LYEL filing catalyst

Why did $LYEL trigger an AI stock catalyst alert?

$LYEL triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +4.5/10). Headline: Lyell Reports Strong Phase 2 PiNACLE Trial Data (91% ORR, 77% CR); Q3 Net Loss Widens to $45.5M. Key points: - Phase 2 PiNACLE trial in 3L+ LBCL shows 91% ORR and 77% CR across 44 efficacy-evaluable patients ahead of ASH 2026. - Q3 2026 GAAP net loss widened to $45.5M vs $38.8M in Q3 2025 on increased R&D spending ($40.9M vs $28.2M). - Commercial revenue remains nominal at $3k.

How did $LYEL stock react after the SEC filing?

After the SEC 8-K for $LYEL, observed market reaction: T0 price $15.43. Past moves do not guarantee future results.

Where can I get real-time $LYEL SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $LYEL via Telegram and the VIP Web Terminal from €10/month.

$LYEL

$LYEL – Lyell Reports Strong Phase 2 PiNACLE Trial Data (91% ORR, 77% CR); Q3 Net Loss Widens to $45.5M

Lyell Immunopharma, Inc.

2026-11-04 00:00:00 UTC · SEC 8-K · All $LYEL

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+4.5 / 10)

Phase 2 PiNACLE trial in 3L+ LBCL shows 91% ORR and 77% CR across 44 efficacy-evaluable patients ahead of ASH 2026.
Q3 2026 GAAP net loss widened to $45.5M vs $38.8M in Q3 2025 on increased R&D spending ($40.9M vs $28.2M).
Commercial revenue remains nominal at $3k.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →